FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-028								

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person*  Tarriff Scott					2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC.									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Taitiii Scott														X	Direc	tor	X	10% C	Owner	
(Last) (First) (Middle)					EGRA J									X	Officer (give title below)				(specify	
					3. Date of Earliest Transaction (Month/Day/Year)									CEO						
<b>'</b>					03/01/2019															
50 TICE BLVD., SUITE 315																				
				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
LIFF NJ	J (	07677												X	Form	filed by One	Repoi	ting Pers	son	
															Form filed by More than One Reporting				orting	
(St	ate) (	Zip)																		
	Tabl	le I - No	n-Deriv	ative	Seci	uritie	s Acc	quired	, Dis	sposed o	f, or l	Ben	eficia	ally C	Owne	ed				
Date					Execution Date /Year) if any		Date,							and 5) Secu Bene Own		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) (D)	or	Price		Transaction(s) (Instr. 3 and 4)				(IIISti. 4)	
Common Stock 03/01/2								S <sup>(1)</sup>		12,000	Ι	D \$50.51		1,537,605			D			
Common Stock 03/01/2								S <sup>(1)</sup>		12,428	D \$		\$51.8	.81(3) 1,		,525,177		D		
	Та	able II -												y Ow	ned					
or Exercise Price of Derivative Security (Month/Day/Year) if any (Month/Day/Year) 8)			Transa Code ( 8)	(Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration			Amoun or Numbe		ount	t r		derivative Securities Beneficially Owned Following Reported	Ov Fo Dii or (I)	nership rm: ect (D) Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	(Figure 1) (Figure 2) (Figure 2) (Figure 3)	(First) (Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) GLE PHARMACEUTICALS, INC. BLVD., SUITE 315  CLIFF NJ 07677  (State) (Zip)  Table I - No Security (Instr. 3)  Stock  Table II -  Conversion or Exercise Price of Derivative Price of Derivative  3. Transaction Date (Month/Day/Year) (Month/I	(First) (Middle) GLE PHARMACEUTICALS, INC. BLVD., SUITE 315  CLIFF NJ 07677  (State) (Zip)  Table I - Non-Deriv Gecurity (Instr. 3)  2. Transac Date (Month/Da Stock 03/01/2  Stock 03/01/2  Table II - Derivat (e.g., pt Or Exercise Price of Derivative Security  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)	SCOTT  (First) (Middle)  GLE PHARMACEUTICALS, INC.  BLVD., SUITE 315  (State) (Zip)  Table I - Non-Derivative  Gecurity (Instr. 3)  2. Transaction Date (Month/Day/Year)  Stock  03/01/2019  Table II - Derivative Security (e.g., puts, c  (e.g., puts, c  (Month/Day/Year)  2. Table II - Derivative Security (if any (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)	(First) (Middle)  GLE PHARMACEUTICALS, INC.  BLVD., SUITE 315  Table I - Non-Derivative Sectority (Instr. 3)  Stock  Stock  Table II - Derivative Security (e.g., puts, calls, recovering in any (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls, recovering in any (Month/Day/Year)  Stock  3. Date of 103/01/20  4. If Amend 22. Transaction Date (Month/Day/Year)  Fable II - Derivative Security (e.g., puts, calls, recovering in any (Month/Day/Year)  Stock  3. Transaction Date (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls, recovering in any (Month/Day/Year)  Stock  3. Date of 103/01/20  4. If Amend 22. Transaction Date (Month/Day/Year)  Stock  3. Date of 103/01/20  4. If Amend 22. Transaction Date (Month/Day/Year)  Stock  3. Date of 103/01/20  4. If Amend 22. Transaction Date (Month/Day/Year)  Stock  4. Transaction Code (Instr. 8)	Conversion or Exercise Price of Derivative Security   Stock   Stock	(First) (Middle)  GLE PHARMACEUTICALS, INC. BLVD., SUITE 315  GLIFF NJ 07677  (State) (Zip)  Table I - Non-Derivative Securities Accurate (Month/Day/Year)  Stock 03/01/2019  Table II - Derivative Securities Acqueeg.g., puts, calls, warrants, (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Stock 03/01/2019  Table II - Derivative Securities Acqueeg.g., puts, calls, warrants, (Month/Day/Year)  3. Transaction Date (Execution Date, if any (Month/Day/Year)  4. If Amendment, Date of Earliest Trans 03/01/2019  2. Transaction Date (Month/Day/Year)  Stock 03/01/2019  Table II - Derivative Securities Acqueeg.g., puts, calls, warrants, (Month/Day/Year)  2. Conversion of Exercise Price of Derivative Securities Acqueeg.g., puts, calls, warrants, (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Stock 03/01/2019  Table II - Derivative Securities Acqueeg.g., puts, calls, warrants, (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Government Date (Month/Day/Year)  Stock 03/01/2019	Circle   Conversion or Exercised   Convers	Code   Conversion or Exercise   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and or Execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date execution Date if any (Month/Day/Year)   Code (Instr. and of Date exec	Code   Code   Code   Conversion   Conversi	EAGLE PHARMACEUTICALS, INC.	Scott   EAGLE PHARMACEUTICALS, INC.   EGRX	Code   Conversion of Exercise   Conversion of Executing   Conversion of Exercise   Conversion	EAGLE PHARMACEUTICALS, INC.   EGRX	EAGLE PHARMACEUTICALS, INC.   EGRX   Survey   Survey	EAGLE PHARMACEUTICALS, INC.   EGRX     Silver   Silver	EAGLE PHARMACEUTICALS, INC.   EGRX	EAGLE PHARMACEUTICALS, INC.   EGRX   Solution   EGRX   EGRX   Solution   EGRX   EGRX   Solution   EGRX   E	

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$50.1615 to \$51.0577 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.3201 to \$52.2003 inclusive.

## Remarks:

03/04/2019 /s/ Scott Tarriff

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.